Back to Search
Start Over
Recreation use of phosphodiesterase type 5 inhibitors, the other side of erectile dysfunction.
- Source :
-
Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica [Arch Ital Urol Androl] 2023 May 29; Vol. 95 (2), pp. 11350. Date of Electronic Publication: 2023 May 29. - Publication Year :
- 2023
-
Abstract
- To the Editor, In 1998 Sildenafil was approved by the Food and Drug Administration as first line therapy for erectile dysfunction. Since then, phosphodiesterase type 5 inhibitors (PDE5i) represent the first-line treatment of erectile dysfunction (ED), improving physiological erectile function, sexual orgasmic function, psychological self-esteem, couples' relationship, and quality of life. [...].
Details
- Language :
- English
- ISSN :
- 2282-4197
- Volume :
- 95
- Issue :
- 2
- Database :
- MEDLINE
- Journal :
- Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica
- Publication Type :
- Academic Journal
- Accession number :
- 37254932
- Full Text :
- https://doi.org/10.4081/aiua.2023.11350